Staffan Schön
Research Scientist
Diabetes and Endocrinology
Stockholm Health Economics
Sweden
Biography
Staffan Schön is a research scientist in both Internal Medicine and in Clinical diabetes and endocrinology in Stockholm Health Economics, Stockholm, Sweden.
Research Interest
Staffan Schön research involves in demonstrated that co-administration of losartan, an angiotensin-II-receptor antagonist, with existing conventional antihypertensive therapy (CT) reduces the risk of development of end-stage renal disease (ESRD) in type 2 diabetes patients with nephropathy compared with CT alone.
